210 related articles for article (PubMed ID: 31045327)
1. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
[TBL] [Abstract][Full Text] [Related]
2. Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell-like Pericytes Defective in Vessel Formation.
Glaser K; Dickie P; Dickie BH
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e495-e504. PubMed ID: 30256265
[TBL] [Abstract][Full Text] [Related]
3. Characterization of kaposiform lymphangiomatosis tissue-derived cells.
Nozawa A; Ozeki M; Yasue S; Endo S; Noguchi K; Kanayama T; Tomita H; Aoki Y; Ohnishi H
Pediatr Blood Cancer; 2021 Oct; 68(10):e29086. PubMed ID: 33913609
[TBL] [Abstract][Full Text] [Related]
4. Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.
Allen-Rhoades W; Al-Ibraheemi A; Kohorst M; Tollefson M; Hull N; Polites S; Folpe AL
Hum Pathol; 2022 Apr; 122():72-81. PubMed ID: 35202617
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
6. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
Adams DM; Ricci KW
Hematol Oncol Clin North Am; 2019 Jun; 33(3):455-470. PubMed ID: 31030813
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of kaposiform lymphangiomatosis with sirolimus.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Jul; 62(7):1291-3. PubMed ID: 25598153
[TBL] [Abstract][Full Text] [Related]
8. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.
Ji Y; Chen S; Peng S; Xia C; Li L
Orphanet J Rare Dis; 2019 Jul; 14(1):165. PubMed ID: 31277673
[TBL] [Abstract][Full Text] [Related]
10. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.
Croteau SE; Kozakewich HP; Perez-Atayde AR; Fishman SJ; Alomari AI; Chaudry G; Mulliken JB; Trenor CC
J Pediatr; 2014 Feb; 164(2):383-8. PubMed ID: 24252784
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
12. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
13. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
15. Kaposiform hemangioendothelioma in the uterine cervix of a 5-year girl.
Zhang H; Luo J; Feng X
Fetal Pediatr Pathol; 2012 Oct; 31(5):273-7. PubMed ID: 22432747
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
17. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
Alonso N; Diaz Nebreda A; Monczor F; Gutkind JS; Davio C; Fernandez N; Shayo C
Biochim Biophys Acta; 2016 Sep; 1860(9):1998-2007. PubMed ID: 27316323
[TBL] [Abstract][Full Text] [Related]
18. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
20. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis.
Zukerberg LR; Nickoloff BJ; Weiss SW
Am J Surg Pathol; 1993 Apr; 17(4):321-8. PubMed ID: 8494101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
